8-K: Viking Therapeutics Announces Positive Results from VK2735 Obesity Program

Viking Therapeutics reported promising data from its VK2735 obesity program, including significant weight loss with both oral and subcutaneous formulations.

Summary

• Viking Therapeutics announced new clinical data from its VK2735 obesity program at ObesityWeek 2024.
• The data includes results from a Phase 1 trial of an oral tablet formulation and follow-up results from the Phase 2 VENTURE trial of a subcutaneous injection.
• The oral tablet study showed up to 8.2% mean weight loss from baseline and 6.8% placebo-adjusted mean weight loss after 28 days of dosing.
• Up to 100% of subjects treated with the oral tablet achieved at least 5% weight loss, compared to 0% for placebo.
• The Phase 2 VENTURE study showed up to 14.7% mean weight loss from baseline after 13 weeks of subcutaneous dosing.
• Up to 88% of patients in the subcutaneous treatment groups achieved 10% weight loss, compared to 4% for placebo.
• The subcutaneous formulation showed durable weight loss effects, with over 80% of the original weight loss maintained seven weeks after the last dose.
• The oral formulation demonstrated encouraging safety and tolerability with most adverse events being mild or moderate.
• The subcutaneous formulation also showed encouraging safety and tolerability with most adverse events being mild or moderate.
• The company plans to discuss the clinical path forward for injectable VK2735 with the FDA and initiate a Phase 2 study of the oral tablet formulation by the end of the year.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with significant weight loss and good tolerability, suggesting a high likelihood of success for VK2735. The management commentary is also very positive.

Positives

• The oral formulation of VK2735 demonstrated significant weight loss, with up to 8.2% reduction from baseline.
• The oral formulation showed a strong response, with up to 100% of subjects achieving at least 5% weight loss.
• The subcutaneous formulation of VK2735 showed substantial weight loss, with up to 14.7% reduction from baseline.
• The subcutaneous formulation demonstrated a high rate of success, with up to 88% of patients achieving 10% weight loss.
• Both formulations showed encouraging safety and tolerability profiles, with most adverse events being mild or moderate.
• The subcutaneous formulation showed durable weight loss effects, with over 80% of the original weight loss maintained seven weeks after the last dose.
• The study suggests the potential for less frequent dosing regimens for the subcutaneous formulation.
• The oral formulation showed potential for lower dose maintenance regimens after initial weight loss induction.
• VK2735 treatment increased the odds of patients with prediabetic status shifting to normoglycemic status.
• The proportion of patients with normal glycemic status transitioning to pre-diabetic status favored VK2735.

Negatives

• Some subjects experienced mild nausea with the oral formulation of VK2735.
• A small percentage of subjects experienced vomiting with the oral formulation of VK2735.
• Some patients experienced nausea and vomiting with the subcutaneous formulation of VK2735.
• The majority of GI-related adverse events occurred early in the treatment period.

Risks

• The clinical trials are still in progress, and further data is needed to confirm the long-term efficacy and safety of VK2735.
• The company needs to obtain regulatory approval from the FDA before commercializing VK2735.
• There is competition from other companies developing similar treatments for obesity and metabolic disorders.
• The company needs to successfully complete Phase 3 trials for the injectable formulation and Phase 2 trials for the oral formulation.
• The company needs to successfully manufacture and scale up production of VK2735.

Future Outlook

Viking plans to discuss the clinical path forward for injectable VK2735 with the FDA later this quarter and expects to initiate a Phase 2 study of the oral tablet formulation by the end of this year. Details of the Phase 3 injectable and Phase 2 oral study designs will be provided closer to study initiation dates.

Management Comments

• We are happy to report the updated results from both the VENTURE Phase 2 study and the oral Phase 1 study, said Brian Lian, Ph.D., chief executive officer of Viking.
• We believe the VENTURE data demonstrate VK2735s promising efficacy and tolerability profile through 13 weeks of weekly dosing and support our belief that less frequent dosing regimens may provide effective maintenance of weight control.
• The updated oral Phase 1 study results continue to demonstrate an encouraging tolerability profile and promising signs of clinical activity at doses of up to 100 mg daily.
• We believe the durable effects observed following 28 days of dosing suggest potential opportunities to introduce lower dose regimens following an initial induction of weight loss.

Industry Context

The announcement is significant in the context of the growing market for obesity treatments, with GLP-1 and dual GLP-1/GIP agonists gaining prominence. Viking's VK2735 is positioned to compete with established drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

Comparison to Industry Standards

• The weight loss results for the subcutaneous formulation of VK2735, with up to 14.7% reduction from baseline, are comparable to or better than some of the results seen with other GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Zepbound).
• The oral formulation of VK2735, with up to 8.2% weight loss from baseline, shows promise in the oral obesity treatment space, which is currently dominated by less effective options.
• The maintenance of weight loss after discontinuation of the subcutaneous formulation is a positive sign, potentially addressing a key challenge with current obesity treatments.
• The safety and tolerability profile of VK2735 appears to be competitive with other GLP-1 and dual agonists, with most adverse events being mild or moderate.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Employees may be motivated by the progress of the company's lead drug candidate.
• Patients with obesity and metabolic disorders may benefit from the development of VK2735.
• The company's success could lead to increased revenue and profitability.

Next Steps

• Viking plans to discuss the clinical path forward for injectable VK2735 with the FDA.
• Viking expects to initiate a Phase 2 study of the oral tablet formulation of VK2735 by the end of this year.
• Details of the Phase 3 injectable and Phase 2 oral study designs will be provided closer to study initiation dates.

Key Dates

Keywords

VK2735, obesity, weight loss, GLP-1, GIP, clinical trial, metabolic disorders, oral formulation, subcutaneous injection, Phase 1, Phase 2, VENTURE study, diabetes, pharmacokinetics